Apixaban

• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 Phase III 16 countries Celgene Corp.
• Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE Recruiting
  2022-500974-33-00 Phase III 1 country Centre Hospitalier Universitaire De Saint Etienne
• SACK Recruiting
  2022-501600-10-00 Phase III 7 countries Karolinska University Hospital; Medical University Of Silesia Katowice Poland
• Preventing formation of blood clots due to atrial fibrillation, a cardiac arrhythmia that first occurred after coronary bypass surgery, with… Recruiting
  2024-515924-35-00 Phase IV 1 country Icahn School Of Medicine At Mount Sinai
• API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a P… Recruiting
  2024-513191-17-00 Phase II 1 country Centre Hospitalier Universitaire De Dijon
• Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long-term parenteral nutrition. Recruiting
  2024-512061-14-00 Phase IV 1 country UZ Leuven
• Optimized pharmacologic treatment for broken heart (takotsubo) syndrome Recruiting
  2022-501874-21-00 Phase IV 3 countries Vastra Gotalandsregionen
• Avoid Anticoagulation After IntraCerebral Haemorrhage Recruiting
  2024-514094-22-00 Phase III 1 country Centre Hospitalier Universitaire De Lille
• Anticoagulant medicines for Balloon Pulmonary Angioplasty Ended
  2024-518803-23-00 Phase IV 1 country St. Antonius Ziekenhuis
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended
  2023-510178-15-00 Phase III 17 countries Celgene Corp.
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended
  2022-501419-15-00 Phase III 19 countries Janssen - Cilag International
• Anticoagulant Regimens Given to achieve thrombus regression and reduce clinical Outcomes among patients with Non device-related intra-cardia… Ended
  2024-512685-33-00 Phase III 1 country Centre Hospitalier Universitaire De Nimes
• DANNOAC- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study Ended
  2022-501912-32-00 Phase IV 1 country Bispebjerg Hospital; Gentofte Hospital
• The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) Ended
  2024-518547-38-00 Phase IV 1 country Rigshospitalet
• APIS Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension Ended
  2024-514348-95-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism Ended
  2023-504179-26-00 Phase IV 1 country Royal College Of Surgeons In Ireland
• Etude de dose de l’acide tranexamique dans la prothèse totale de hanche pour réduire la perte d’hémoglobine post-opératoire. Etude de phase … Ended
  2022-502532-38-01 Phase II 1 country Centre Hospitalier Universitaire De Saint Etienne
• RANDOMISED, CROSSOVER BIOEQUIVALENCE CLINICAL TRIAL OF APIXABAN 5 MG CAPSULES VS APIXABAN 5 MG FILM-COATED TABLETS, AFTER A SINGLE ORAL DOSE… Ended
  2023-506035-15-00 1 country Laboratorios Alter S.A.
• A trial to learn how well REGN9933 works for preventing blood clots after knee replacement surgery in adult participants Ended
  2022-501470-18-00 Phase II 6 countries Regeneron Pharmaceuticals Inc.
• Randomised, crossover bioequivalence clinical trial of apixaban 5 mg film-coated tablets, after a single oral dose administration to healthy… Ended
  2023-503557-35-00 1 country Alter Farmacia S.A.
• Bioequivalence clinical trial of two formulations of apixaban Ended
  2023-503970-19-00 1 country Laboratorios Normon S.A.
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended
  2023-503794-38-00 Phase III 22 countries Bayer AG
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on… Ended
  2023-509569-19-00 Phase II/III 12 countries Anthos Therapeutics Inc.
• Blood thinners after transcatheter implantation of a new heart valve in patients with aortic stenosis Ended
  2023-510211-20-00 Phase III 1 country Oslo University Hospital HF

Showing 25–48 of 50 trials